
Himalaya Nutravedics India IPO
LISTEDSMEHNILListing Performance
▲ 11.32%
Issue Price
₹106
Listing Price
₹118
Listed On
29 Sep 2026
- Price Band
- ₹100 – ₹106
- Lot Size
- 1,200
- Lot Value
- ₹1,27,200
- Open Date
- 22 Sep22 Sep 2026
- Close Date
- 24 Sep24 Sep 2026
- Min Investment
- ₹1,27,200
About Himalaya Nutravedics India
Himalaya Nutravedics manufactures and supplies a range of Ayurvedic and nutraceutical products across multiple dosage forms, including softgel capsules, hardgel capsules, tablets, liquid orals, medicated oils, and protein powders. The company operates through a single integrated manufacturing facility located in Hyderabad, Telangana. Its product portfolio covers therapeutic categories such as pain management, infertility, women’s wellness, gut health, neurological support, and general wellness. The business generates revenue primarily from the sale of Ayurvedic formulations, alongside nutraceutical offerings. The company operates mainly through a business-to-business model, supplying products to stockists, distributors, and third-party contract manufacturing clients across various states in India. It also undertakes custom contract manufacturing for corporate clients under their own brand names utilizing its manufacturing infrastructure. Furthermore, the company is expanding its market presence into direct-to-consumer sales channels through digital platforms, e-commerce marketplaces, and quick commerce delivery services.
Manufactures Ayurvedic and nutraceutical products for branded and contract manufacturing business.
Use of IPO Proceeds
Promoters
Chanda Asawa
Promoter · age 60
Over 07 years
She does not hold any professional educational qualification.
Divya Asawa
Promoter
Rama Raju Penmatsa
Promoter · age 65
Over 0.4 year
He does not hold any professional educational qualification.
Rohit Asawa
Promoter
Investment Analysis
Quick Analysis: 5 strengths · 5 risk factors· Exchange: BSE SME
Strengths (5)
- •Integrated manufacturing facility capable of producing multiple dosage forms.
- •Diverse Ayurvedic and nutraceutical product portfolio across key therapeutic areas.
- •Established B2B distribution network with presence across 17 Indian states.
- •Track record of strong revenue and net profit growth over recent fiscal years.
- •In-house quality assurance and control capabilities across production processes.
Risk Factors (5)
- •High revenue reliance on Ayurvedic products, accounting for over 90% of sales.
- •Significant revenue concentration from top 10 customers representing over 80% of revenue.
- •Operations from a single leased manufacturing facility located in Hyderabad, Telangana.
- •Pending trademark opposition proceedings for corporate logos and mark applications.
- •History of negative cash flows from operating activities due to working capital needs.
Demand snapshot
Subscription and grey market data as reported. Not a recommendation.
- Subscribed 2.23x (QIB 1.00x, NII 2.87x, Retail 2.56x) at close
Investor Quota
Approx. shares reserved per category
Estimated from total issue size; actual reserved lots are set in the RHP.
Application Lot Sizes
Retail caps at ₹2,00,000 (1 lots here). S-HNI is ₹2L–₹10L, B-HNI is above ₹10L.
| Category | Lots | Shares | Amount |
|---|---|---|---|
| Retail (min) | 1 | 1,200 | ₹1,27,200 |
| Retail (max) | 1 | 1,200 | ₹1,27,200 |
| S-HNI (min) | 2 | 2,400 | ₹2,54,400 |
| S-HNI (max) | 7 | 8,400 | ₹8,90,400 |
| B-HNI (min) | 8 | 9,600 | ₹10,17,600 |
Subscription Status
| Category | Day 1 | Day 2 | Day 3 |
|---|---|---|---|
| QIB | — | — | 1.00x |
| sNII (S-HNI) | — | — | — |
| bNII (B-HNI) | — | — | — |
| Retail | 0.16x | 0.66x | 2.56x |
| Total | 0.10x | 0.41x | 2.23x |
Colour: red <1x · amber 1–10x · green ≥10x oversubscribed.
Allotment Statistics
Retail Individual Investors (RII)
Subscription
2.56x
Allotment Ratio
1 lot per 3 applicants
Allotment Probability
~39.1%
Non-Institutional Investors (NII / HNI)
Subscription
2.87x
Allotment Type
Proportionate allotment
Qualified Institutional Buyers (QIB)
Subscription
1.00x
Allotment Type
Discretionary allotment
Total Subscription
2.23x
Allotment probability is estimated based on subscription data and is not guaranteed. Actual allotment depends on the registrar's process.
Basis of Allotment
Category-wise subscription & allotment ratio
Weigh your chances
IPO Timeline
Issue Opens
22 Sep 2026 · Tue
Issue Closes
24 Sep 2026 · Thu
UPI Deadline
24 Sep 2026 · Thu
Allotment
25 Sep 2026 · Fri
Refund
28 Sep 2026 · Mon
Share Credit
28 Sep 2026 · Mon
Listing
29 Sep 2026 · Tue
Issue Opens
22 Sep 2026 · Tue
Issue Closes
24 Sep 2026 · Thu
UPI Deadline
24 Sep 2026 · Thu
Allotment
25 Sep 2026 · Fri
Refund
28 Sep 2026 · Mon
Share Credit
28 Sep 2026 · Mon
Listing
29 Sep 2026 · Tue
IPO Details
| Registrar | KFin Technologies Limited |
| Exchange | BSE SME |
| ISIN | — |
| Face Value | ₹10 |
| Issue Size | ₹26.50 Cr |
| Fresh Issue | — |
| OFS Size | — |
| Lead Managers | NIRBHAY CAPITAL SERVICES PRIVATE LIMITED |
3-Year Financial Summary
Revenue trend
↑ FY24→FY26
| Fiscal Year | Revenue (₹Cr) | PAT (₹Cr) | EPS | P/E | ROE |
|---|---|---|---|---|---|
| FY26 | 43.07 | 7.39 | 18.47 | 5.74 | 45.12% |
| FY25 | 21 | 2.23 | 5.58 | 19.00 | 33.08% |
| FY24 | 14.43 | 0.43 | 1.07 | 99.53 | 31.77% |
Detailed Line Items (₹ Cr)
| Line Item | FY24 | FY25 | FY26 |
|---|---|---|---|
| Total Income | 14.43 | 21 | 43.12 |
| EBITDA | 0.94 | 2.99 | 8.1 |
| Net Worth | 1.34 | 6.75 | 16.38 |
From the company's offer document (DRHP/RHP); restated figures where available.
Valuation at Issue Price
Issue P/E
5.7x
Price ÷ EPS
EPS (FY26)
₹18
Earnings per share
RoNW
45.12%
Return on net worth
ROCE
—
Not in abridged DRHP
EBITDA margin
18.8%
EBITDA ÷ revenue
Price/NAV
4.08x
Price ÷ NAV (as reported)
Check the valuation yourself
Company Fundamentals
14 sections extracted from this filingCapital Structure
| Authorised Capital | ₹10.00 Cr |
| Issued Capital | ₹6.31 Cr |
| Paid-up Capital | ₹6.31 Cr |
| Equity Shares (Pre-Issue) | 40,00,000 |
| Equity Shares (Post-Issue) | 63,06,720 |
Source: Himalaya Nutravedics India offer document (DRHP/RHP).
Shareholding Pattern
Pre-Issue
- Rohit Asawa(Promoter)+4.95%
- Divya Asawa(Promoter)+25.55%
- Chanda Asawa(Promoter)+45.38%
- Sneha Penmatsa(Promoter)+8.00%
- Krishna Kiran Kakarlapudi(Promoter)+16.00%
- Umesh Chand Asawa(Promoter)+0.13%
Post-Issue
- Rohit Asawa(Promoter)+4.71%
- Divya Asawa(Promoter)+24.31%
- Chanda Asawa(Promoter)+43.17%
- Rama Raju Penmatsa(Promoter)+15.22%
- Swati Penmatsa(Promoter)+7.61%
- Umesh Chand Asawa(Promoter)+0.08%
Source: Himalaya Nutravedics India offer document (DRHP/RHP).
Reservations & OFS
Investor Reservation
- Anchor60.00%
- QIB50.00%
- NII / HNI15.00%
- Retail35.00%
OFS Selling Shareholders
No offer-for-sale component (or sellers not disclosed).
Source: Himalaya Nutravedics India offer document (DRHP/RHP).
Board & Management
Board of Directors (4)
- Rohit Asawa₹0.24 Cr p.a.
Chairman and Managing Director
Founder with background in financial management, cost control and operational accuracy
- Divya Asawa₹0.00 Cr p.a.
Non-Executive Director
- Abhisheak Dhoot₹0.00 Cr p.a.
Independent Director
Bachelor of Commerce, Associate Member of the Institute of Chartered Accountants of India
Over 8 years of experience in taxation, auditing and financial advisory
- Ramya Inala₹0.00 Cr p.a.
Independent Director
Bachelor of Arts and Bachelor of Laws (B.A., LL.B) from PG College of Law, Osmania University; Company Secretary
Over 7 years of experience in legal, corporate secretarial and advisory matters
Key Managerial Personnel (2)
- Krishna Kanth Sarda
Chief Financial Officer
Bachelor's degree in Commerce from Osmania University, Hyderabad; Diploma in Management from Aurora's Business School, Hyderabad
Over 5 years in accounting and finance industry
- Pooja Biyani
Company Secretary and Compliance Officer
Provisional degree in Bachelor's of Commerce from Osmania University, Hyderabad; Associate member of the Institute of Company Secretaries of India
Over 3 years in secretarial industry
Source: Himalaya Nutravedics India offer document (DRHP/RHP).
Industry & Market
Per Infomerics Analytics & Research, a report commissioned by the company (not independent).
Peer Comparison
| Company | P/E | EPS | RoNW % | NAV |
|---|---|---|---|---|
| Himalaya Nutravedics India Limited | — | 12.05 | 45.12 | 26.7 |
| Jeena Sikho Lifecare Limited | 28.75 | 17.84 | 27.67 | 37.6 |
| Sandu Pharmaceuticals Limited | 20.62 | 1.83 | 2.53 | 45.21 |
Material Litigation
| Type | Against | Matters | Amount (₹Cr) |
|---|---|---|---|
| Tax | Company | 1 | 0.273 |
Direct tax case regarding disallowed Section 80-IAC deduction; appeal pending with appellate authority
Registrar (RTA)
SEBI-registered Registrar & Transfer Agent — handles allotment and refunds.
Registrar:KFin Technologies Limited→Lead Managers (BRLMs)
Click any merchant banker for their full IPO track record (positive listing rate, average gain, IPOs managed).
Documents
Frequently Asked Questions
When is the Himalaya Nutravedics India IPO opening?
The Himalaya Nutravedics India IPO opens on 22 Sep 2026 and closes on 24 Sep 2026. Check this page for the latest updates as we refresh every 30 minutes.
What is the price band of the Himalaya Nutravedics India IPO?
The price band for the Himalaya Nutravedics India IPO is ₹100 to ₹106. The final price is announced after the book-building process and is confirmed before listing.
What is the lot size and minimum investment for the Himalaya Nutravedics India IPO?
The minimum lot size is 1200 shares with a minimum investment of ₹1,27,200. Retail investors can apply for up to the retail limit defined by SEBI.
What is the GMP of Himalaya Nutravedics India IPO today?
The latest Grey Market Premium for Himalaya Nutravedics India is ₹0 (+0.00%). GMP is unofficial data and is not a guarantee of listing price.
When will the Himalaya Nutravedics India IPO list on NSE and BSE?
The Himalaya Nutravedics India IPO is expected to list on 29 Sep 2026 on BSE SME. Actual listing day trading begins at the start of the normal market session.
How can I check the Himalaya Nutravedics India IPO allotment status?
The registrar for this IPO is KFin Technologies Limited. You can check your allotment status on the registrar's portal using your PAN, application number, or DP ID. We link to the registrar directly on our allotment page after the allotment date.
Is the Himalaya Nutravedics India IPO a mainboard or SME issue?
Himalaya Nutravedics India is a SME IPO that will list on the NSE Emerge or BSE SME platform. SME IPOs require a minimum application value of one lakh rupees.
How do I apply for the Himalaya Nutravedics India IPO?
You can apply for the Himalaya Nutravedics India IPO through any SEBI-registered broker such as Zerodha, Upstox, or Angel One using UPI or ASBA while the issue is open for bidding.
What is the GMP-implied price of Himalaya Nutravedics India IPO?
The GMP-implied price (unofficial, not a forecast) is ₹106: the upper price band of ₹106 plus the latest grey market premium of ₹0, as of 29 Sep 2026, 11:33 PM IST. GMP is unofficial grey market data, and the actual listing price can differ from it.
What is the allotment ratio for Himalaya Nutravedics India IPO?
Based on the retail subscription of 2.56x, the estimated allotment ratio is 1 lot per 3 applicants (approximately 39.1% chance of allotment). This is an estimate and actual allotment may vary.
Recently Listed IPOs
| Company | Listed | Listing Gain |
|---|---|---|
| Antala Industries | 11 Nov 2026 | -20.00% |
| Vedant Poly Fabs | 09 Nov 2026 | +0.00% |
| Maxwell Engineering Solutions | 06 Nov 2026 | +90.00% |
Related IPOs
Related Articles
How NRIs Can Apply for IPOs Through Zerodha: Rules, Accounts and Limits
NRIs can apply for Indian IPOs through Zerodha using NRE/NRO accounts via UPI or ASBA. Here is how the process works, what accounts you need, and the SEBI/RBI holding limits that apply.
Read more →
How-ToHow to Use 10 Minutes of Research to Validate Any IPO Video You Watch
SEBI now requires issuers to publish a 10-minute IPO disclosure video. Here is a practical, source-by-source method to verify what you watch against the DRHP and official exchange records in about ten minutes.
Read more →
How-ToHow to Read Past IPO Data to Set Realistic Listing Gain Targets
Median listing gains fell to 3.8% in 2025 from 15.2% in 2024. Here is how to read past IPO data, GMP, and subscription numbers to set realistic listing day expectations instead of chasing hype.
Read more →